Procedures
infection
VIRUS, ADVERSE EVENTS, RECRUITMENT, INFECTION, ADVERSE EVENT, PLAQUE, EVENTS, YELLOW FEVER
Upon recruitment, baseline blood samples were collected to assess CD44 mL venous blood samples were collected before vaccination to assess presence of yellow fever antibodies in serum from previous infection or vaccination, 10 days after vaccination to assess rapidity of immunological protection, 28 days after vaccination to assess immunogenicity (primary outcome), and 1 year after vaccination to assess the longevity of the antibodies. Whole blood samples were separated by centrifugation to collect serum within 4 h of collection and stored at –80°C at the Kenya Medical Research Institute—Wellcome Trust Research Programme's repository and later shipped to Institute Pasteur de Dakar (Dakar, Senegal) for virus neutralisation tests.Immunogenicity was tested using a standardised plaque reduction neutralisation test (PRNT), the gold standard for evaluating functional immunity in response to yellow fever vaccination.Any adverse event regardless of seriousness was actively monitored and recorded within 30 minutes after vaccination, at the scheduled study visits (day 10, day 28), and any unscheduled visits within 28 days of vaccination. Participants were also advised to report any substantial health events to the research clinic during the entire duration of the trial. Serious adverse events